Skip to content

Home
Über uns
Onkologie
Labordienstleistungen
Anteilseigner
News
Kontakt
Deutsch

Menü

Home
Über uns
Onkologie
Labordienstleistungen
Anteilseigner
News
Kontakt
Deutsch

Veröffentlichungen

Investoren

Finanziell
Berichte

Analytiker
Berichte

Pressemeldungen

Anteilseigner

Investoren

Finanziell Berichte

Analystenberichte

Pressemeldungen

Anteilseigner

Invitrocue announces acquisition of Welala to create life science leadership in Thailand and Asean

September 23, 2024

Invitrocue’s Onco-PDO test is Singapore’s and world’s first validated and approved Clinical Cancer Drug Screening service for Personalised Oncology

März 5, 2024

Operational Updates – February 2024

Februar 7, 2024

Operational Updates – October 2023

November 9, 2023

Thailand FDA grants approval for commercial use of MyTruHealth and MyTruAge DNA Methylation Test Kit

August 18, 2023

Singapore’s Ministry of Health grant license approval for commercial use for Onco-PDO™ – Personalized Cancer Drug Screening

Juli 13, 2023

International MOU inked between chemistry and biomedical talents from Hong Kong, Singapore and Europe for late-stage cancer research enhancement.

Juli 27, 2022

Operational Updates and Management Accounts

Februar 18, 2022

Quarterly Updates – March 2021

Mai 3, 2021

Delisting from ASX Official List

Februar 26, 2021

Appendix 4C – quarterly

Februar 1, 2021

4C Commentaries and Management Updates

Mai 1, 2020

Appendix 4C – quarterly

April 30, 2020

Board Changes – 3 Mar 2020

März 3, 2020

Invitrocue enters MOU to establish a Joint Venture for Brazilian and Latin American Market

Februar 11, 2020

Appendix 4C – Commentaries & Management Updates

Februar 6, 2020

Quarterly Appendix 4C – December 2019

Januar 1, 2020

Cleansing prospectus

Dezember 17, 2019

Change of Director's Interest Notice – Dr Andreas Lindner

Dezember 17, 2019

Proposed issue of Securities – IVQ

Dezember 17, 2019

Significant investment and joint venture with a fund

Dezember 9, 2019

Results of Annual General Meeting – 2019

November 28, 2019

Quarterly Appendix 4C

November 1, 2019

Notice of Annual General Meeting – 2019

Oktober 30, 2019

Appendix 4E – 2019

Oktober 21, 2019

Invitrocue Establishes Hong Kong Laboratory

Oktober 21, 2019

Invitrocue Clinical Studies underway in Germany

Oktober 21, 2019

Annual Report – 2019

Oktober 3, 2019

Appendix 3B – September 2019

September 9, 2019

Collaboration with National University Hospital Singapore

September 9, 2019

Quarterly Appendix 4C and Business updates

September 9, 2019

Invitrocue Appoints Global Insurance Advisor

Mai 6, 2019

Quarterly Appendix 4C and Business updates

April 30, 2019

Appendix 3B – March 2019

April 30, 2019

Cleansing Statement – April 2019

April 30, 2019

Appendix 3Z – Jamie Khoo – March 2019

März 15, 2019

Appendix 3X – Kit Wei Lui – March 2019

März 15, 2019

Board Changes – March 2019

März 12, 2019

Cleansing Statement – March 2019

März 6, 2019

Appendix 3B – March 2019

März 6, 2019

Appendix 4D – Half Yearly Report and Accounts

März 4, 2019

Invitrocue Appoints Professor Arial Zeng Yi as Patient Derived Organoid Consultant

Februar 19, 2019

Invitrocue creates Joint Venture with A*STAR scientist Dr. Chen Qingfeng

Februar 11, 2019

Quarterly Appendix 4C and Business updates

Februar 1, 2019

IVQ technology development agreement with SIBCB on breast cancer.

Januar 23, 2019

Invitrocue roll-out of Onco-PDO services in Germany

Januar 21, 2019

Invitrocue Appoints Renowned Oncology Researcher Professor Jesús García-Foncillas as Clinical Advisor

Januar 15, 2019

Expiry of unlisted options – Jan 2019

Januar 15, 2019

Final Director's Interest Notice

Januar 11, 2019

Invitrocue Appoints Professor Masakazu Toi as Clinical Advisor

Januar 11, 2019

Invitrocue announced Board Changes

Januar 9, 2019

Change of Director's Interest Notice

Dezember 27, 2018

Change of Director's Interest Notice

Dezember 21, 2018

Change of Director's Interest Notice

Dezember 19, 2018

Change of Director's Interest Notice

Dezember 18, 2018

Change of Director's Interest Notice

Dezember 18, 2018

Change of Director's Interest Notice

Dezember 18, 2018

Appendix 3B – December 2018

Dezember 17, 2018

Cleansing Statement – December 2018

Dezember 17, 2018

Results of Annual General Meeting

November 30, 2018

Dr Lindner as Europe CEO and Prof Waugh as Senior Advisor

November 19, 2018

Quarterly Appendix 4C and Business updates

November 1, 2018

Notice of Annual General Meeting/Proxy Form

Oktober 30, 2018

Initial Director's Interest Notice – Dr Gary W Pace

Oktober 23, 2018

Appointment of Dr. Gary W. Pace as director

Oktober 23, 2018

Assoc Prof Iyer as Chair of IVQ Medical Advisory Board

Oktober 22, 2018

Annual Report to shareholders

September 28, 2018

Appendix 4G

September 28, 2018

Notice of Ceasing to be a Substantial Holder

September 10, 2018

Business updates

September 4, 2018

Preliminary Final Report

August 31, 2018

Change in substantial holding

August 28, 2018

Appendix 4C – quarterly

Juli 31, 2018

Expiry of Unlisted Warrants

Juli 17, 2018

Expiry of Unlisted Warrants

Juli 2, 2018

Cleansing statement

Juni 28, 2018

Appendix 3B

Juni 28, 2018

Proposed issue of securities

Juni 26, 2018

Change in substantial holding

Mai 25, 2018

Appendix 4C – quarterly

April 30, 2018

Appendix 4G

April 27, 2018

IVQ launches Personalised Cancer Screening Service Onco-PDO

April 13, 2018

Half Yearly Report and Accounts

Februar 28, 2018

Grant from Northern Ireland to commercialize Onco-PDO

Februar 26, 2018

Investor Presentation

Februar 23, 2018

Change of Director's Interest Notice – Jamie Khoo

Februar 20, 2018

Change of Director's Interest Notice – Steven Fang

Februar 20, 2018

Change of Director's Interest Notice

Februar 14, 2018

Change of Director's Interest Notice

Februar 14, 2018

Change of Director's Interest Notice

Februar 14, 2018

Change of Director's Interest Notice

Februar 14, 2018

Change of Director's Interest Notice

Februar 14, 2018

Initial Director's Interest Notice

Februar 12, 2018

Appendix 3B

Februar 9, 2018

Appointment of non-executive director

Februar 7, 2018

Appendix 4C & quarterly business update

Januar 31, 2018

Appendix 3B

Januar 29, 2018

IVQ successfully grows liver cancer organoids

Januar 18, 2018

Escrow Release

Januar 15, 2018

Cleansing Statement

Dezember 8, 2017

Appendix 3B

Dezember 8, 2017

Proposed Issue of Securities

Dezember 7, 2017

Results of Annual General Meeting

November 30, 2017

2017 AGM Presentation

November 30, 2017

Cleansing Statement

November 13, 2017

Appendix 3B

November 13, 2017

Proposed issue of securities

November 10, 2017

Quarterly Business Update and Investor Calls

Oktober 31, 2017

Appendix 4C – Quarterly Report

Oktober 30, 2017

Notice of Annual General Meeting/Proxy Form

Oktober 30, 2017

Annual Report to Shareholders

September 29, 2017

Appointments to the Management Team

September 28, 2017

Preliminary Final Report

August 31, 2017

IVQ receives award from Singapore government IP office

August 29, 2017

Investor Presentation

August 29, 2017

Appendix 4C – Quarterly Report and Business Update

Juli 31, 2017

Launch of New Joint Innovation Laboratory to Advance Personalised Medicine for Cancer Treatment

Juli 24, 2017

Invitrocue to work with Garvan Institute to Progress Personalised Real-time Screening of Cancer Drugs

Juli 3, 2017

Cleansing Statement

Juni 30, 2017

Appendix 3B – New Issue Announcement

Juni 30, 2017

Proposed Issue of Securities

Juni 29, 2017

Corporate Governance Statement

Mai 26, 2017

Invitrocue Expands Into In-Vitro Skin and Wound Healing Assays

Mai 22, 2017

Response to ASX Appendix 4C Query

Mai 11, 2017

Appendix 4C – Quarterly Report

April 28, 2017

Appendix 4D – Half Yearly Report and Accounts

Februar 28, 2017

Invitrocue Signs Research Collaboration Agreement with the Garvan Institute of Medical Research

Februar 23, 2017

Appendix 4C – Quarterly Report

Januar 30, 2017

Escrow Release

Januar 3, 2017

Results of Annual General Meeting 2016

November 30, 2016

Invitrocue Appoints DasGupta Ramanuj, Ph.D as Senior Scientific Director

November 24, 2016

Appendix 4C – Quarterly Report

Oktober 31, 2016

Annual General Meeting 2016

Oktober 28, 2016

Invitrocue Signs Research Collaboration Agreement with Genome Institute of Singapore for Colorectal Cancer Organoids

Oktober 24, 2016

Annual Report For The Period Ended 30 June 2016

September 30, 2016

Addendum To Appendix 4E

September 8, 2016

InvitroCue Awarded A*STAR Tender

September 6, 2016

Preliminary Final Report

August 31, 2016

Appendix 3B – New Issue Announcement

August 30, 2016

InvitroCue Signs Strategic Partnership Agreement With QIAGEN Suzhou

August 22, 2016

Escrow Release

August 16, 2016

InvitroCue Announces New Program Focused on Hepatitis B Virus

Juli 28, 2016

Appendix 4C – Quarterly Report

Juli 28, 2016

Investment Fact Sheet July 2016

Juli 11, 2016

InvitroCue Commences Pancreatic Toxicity Assay Development

Juli 11, 2016

Notification of Change of Auditor

Juli 7, 2016

Investor Presentation (Mandarin)

Juni 14, 2016

Investor Presentation 16 May 2016

Mai 16, 2016

InvitroCue Announces Malaria Initiative

Mai 16, 2016

InvitroCue Expands 3D Cell-based Platform for Oncology

Mai 12, 2016

Appendix 4C – Quarterly Report

April 27, 2016

InvitroCue and SciKon Innovation Forge an Alliance to Create the Future of Perfused Human Liver Tissue

April 8, 2016

InvitroCue Launches Cellacyl: Proprietary Acyl Glucuronide Detection Assay

April 8, 2016

New Issue Announcement

März 30, 2016

Initial Director's Interest Notice

März 24, 2016

New Issue Announcement

März 23, 2016

Becoming a Substantial Holder – Steven Fang

März 15, 2016

Agreement with London School of Hygiene & Tropical Medicine

März 9, 2016

Novel 3D in vitro Techniques for Modeling leishmaniasis

März 9, 2016

Operations Update

März 8, 2016

InvitroCue Expands Cell-based Lab in Suzhou to Meet Client’s Increase China Focus

März 5, 2016

Half Yearly Report

Februar 29, 2016

Investor Presentation

Februar 15, 2016

Operations Update

Februar 8, 2016

Becoming a Substantial Holder – Clearbridge Accelerator

Februar 2, 2016

ImageIQ And InvitroCue Forge Partnership To Advance Quantitative Image Analysis For Preclinical Researchers In Asia

Februar 1, 2016

NCCS And InvitroCue To Develop Quantitative Cancer Imaging And Radiomics Applications For Treatment Of Liver Cancer Patients

Januar 28, 2016

Market Release: Reinstatement To Official Quotation

Januar 22, 2016

InvitroCue and Swiss InSphero MOU Signing Ceremony

April 8, 2015

IN KONTAKT KOMMEN

Hildegardstraße 9
80539 Munich
Germany

+49 89 998 209 480

contact.de@invitrocue.com

SAC - SINGLAS Accredited Laboratory

Dienstleistungen

Home
Über uns
Onkologie
Labordienstleistungen
Anteilseigner
News
Kontakt

Icon-twitter-x Facebook-f Linkedin-in Youtube

© Copyright 2025 Invitrocue. Alle Rechte vorbehalten
Impressum | Datenschutz | Cookie-Richtlinie | Cookie-Einstellungen